Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp92 | Diabetes & complications 2 | ECE2017

Non-genetic rat model of nephropathy in type 2 diabetes with attenuated streptozotocin-induced tubular alteration

Bayrasheva Valentina , Babenko Alina , Pchelin Ivan , Arefjeva Anna , Chefu Svetlana , Shatalov Ivan , Dmitriev Yurii , Ivanova Alexandra , Andoskin Pavel , Aliev Parvis , Grineva Elena

Non-genetic animal models of diabetic nephropathy (DN) are most commonly reproduced by using streptozotocin (STZ) which preferentially gets into β-cells via GLUT2 transporters. However, STZ administration results in nephrotoxic effects as well, due to expression of GLUT2 by renal tubular epithelial cells. We hypothesized that nicotinamide (NA), which is considered to attenuate the severity of STZ-induced β-cell damage, could also prevent tubular alteration. Starting ...

ea0026s10.1 | New developments in the therapy for NETs | ECE2011

New developments in the therapy for NETs: risk stratification

Pavel M

Neuroendocrine tumors (NETs) represent a rare and diverse group of tumors with predominant location in the gastro-entero-pancreatic and bronchopulmonary system. At initial diagnosis 50% of the patients present with metastatic disease whereas more than 80% develop metastases in the course of the disease with liver metastases as the most frequent ones. In consideration of the variable and sometimes indolent tumor growth behaviour, risk stratification is an important need for the...

ea0035p995 | Thyroid (non-cancer) | ECE2014

Hyperthyroidism one of the cause of pulmonary hypertension

Dokupilova Adriana , Payer Juraj , Vahala Pavel

Introduction: Hyperthyroidism is a common endocrine disorder that is associated with prominent cardiovascular manifestations. Recent studies also suggest a potential link between hyperthyroidism and pulmonary hypertension (PH). Right-sided heart failure with clinical manifestation is only occasionally seen in patients with Graves’ disease. The prevalence and pathogenic mechanisms of hyperthyroidism-related PHT remain unclear but based on literary data an autoimmune mechan...

ea0081ep730 | Pituitary and Neuroendocrinology | ECE2022

Hypogonatropic hypogonadism with craniopharyngioma in adults before and after surgery.

Klockova Irina , Astafieva Ludmila , Kalinin Pavel , Kutin Maksim , Konovalov Aleksandr

Craniopharyngiomas (CF) - a benign tumor of the embryologic origin. The surgical method of treatment is the basic.Objective: to estimate incidence of hypogonatropic hypogonadism before and after surgical treatment of CF at different topographical variations, and after the preservation of the pituitary stalk. Methods: The research involved 79 patients older than 18 years (41 women and 38 men) with a mean age - 40 [17; 69] with a ver...

ea0081ep741 | Pituitary and Neuroendocrinology | ECE2022

Growth hormone deficiency due to a rare central nervous system tumor

Gabriela Duta Simona , Pavel Sebastian , Stoica Sergiu , Fica Simona

Introduction: Short stature is a common reason for pediatric endocrine evaluation and it can have a variety of causes, including constitutional, genetic short stature, dysmorphic syndromes, chronic illnesses and also endocrine disorders. Growth hormone deficiency accounts for 8% of the cases and it can be isolated or associated with other pituitary hormones deficiencies, congenital or acquired, such as in central nervous system tumors.Case report: A 15-y...

ea0090p44 | Calcium and Bone | ECE2023

CYP24A1 mutation - a rare cause of hypercalcemia and nephrocalcinosis in adulthood

Brunerova Ludmila , Reeš Ondrej , Zoubkova Veronika , Votypka Pavel

Background: CYP24A1 gene encodes the enzyme vitamin D 24-hydroxylase, which converts active vitamin D to inactive metabolites. More than 20 currently described, usually biallelic pathogenic variants of this gene are responsible for idiopathic infantile hypercalcemia manifested typically in childhood (often in newborns) with hypercalcemia, hypercalciuria and nephrocalcinosis. However, a few patients (mostly with monoallelic heterozygous pathogenic variant) can develop mild symp...

ea0063p116 | Calcium and Bone 1 | ECE2019

Successful removal of parathyroid cancer metastasis from VI thoracic vertebra

Mokrysheva Natalia , Krupinova Julia , Gorbacheva Anna , Teplyakov Valeriy , Rumyantsev Pavel

Background: Approximately 25% of patients with parathyroid carcinoma (PC) have metastases; the most frequent sites include cervical lymph nodes (30%) and lungs (40%). Less common are liver, bones and brain. Surgical resection of local or distant metastases (if possible) provides the best control of hypercalcemia and enhances long-term survival.Case description: A 70-year old patient was admitted to hospital with a primary hyperparathyroidism (PH). He did...

ea0063p274 | Pituitary and Neuroendocrinology 1 | ECE2019

Functioning gonadotroph adenoma in a 46 years old male

Pavel Mihai Lucian , Sirbu Anca Elena , Fica Simona

Introduction: Functioning gonadotroph adenomas (FGA) are adenomas secreting and expressing biologically active gonadotropins and causing distinct clinical manifestations. The vast majority of the immunohistochemically confirmed gonadotroph adenomas are hormonally silent (presenting only with mass effects), clinically FGA’s being very rare; whereas their exact prevalence is not known.Case study: A 46 years old male patient presents to our clinic afte...

ea0063p1075 | Pituitary and Neuroendocrinology 3 | ECE2019

Emotional disorders in the clinic of the thyrotropinoma

Sidneva Yuliya , Astafyeva Ludmila , Zaitsev Oleg , Kalinin Pavel , Kadashev Boris

Thyrotropinoma (TSH-secreting pituitary adenomas, TSH-AG) are rare tumor of the pituitary (0.5–2% of all pituitary adenomas). Localization of the tumor with the appropriate neuroendocrine disorders has features in the clinic. This is due to the direct damage to the nucleus and structures of the pituitary with hypersecretion of TSH, which leads to overstimulation of the thyroid gland and the emergence of the clinical picture of ‘central’ hyperthyroidism. Differen...

ea0063ep97 | Pituitary and Neuroendocrinology | ECE2019

Restoration of fertility in a woman with giant prolactinoma in response to cabergoline treatment (case report)

Astaf'eva Liudmila , Kadashev Boris , Kalinin Pavel , Sidneva Yuliya , Melnichenko Galina

A 32-year-old woman presented with primary amenorrhea, prolactin (PRL) level of 154150 mIU/l (40–530 mIU/l) diagnosed with an endo-supra-infra-laterosellar giant pituitary adenoma measuring maximum 6.2 cm. The patient was prescribed a treatment with cabergoline (CAB) at an initial dose of 0.5 mg per week. The treatment decreased the tumour size and brought to normal the level of PRL. After 7 months of CAB treatment menarche was achieved, after 12 months the patient became...